Science Corporation, led by Max Hodak (former Neuralink president and co-founder), has implanted its first vision-restoring brain-computer interface chip in a patient with Stargardt disease, a form of progressive retinal degeneration. The implant represents a significant milestone in applying neural interface technology to restore sensory function.

The procedure demonstrates the expanding scope of brain-computer interfaces beyond research and communication applications into therapeutic restoration of lost biological function. Science Corporation's approach builds on Neuralink's neural interface expertise while focusing specifically on vision restoration.

What This Means for Your Business

Investors in healthcare technology and assistive devices should monitor this space closely—successful vision restoration could represent a multi-billion-dollar market. Regulatory pathways for neural implants are becoming clearer, suggesting faster approval timelines. If you're in insurance, patient services, or disability care, prepare for potential new treatment options and consider how coverage policies may evolve as these therapies move from experimental to standard of care.